AngioDynamics, Inc. (NASDAQ:ANGO) Position Boosted by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 142.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 911,443 shares of the medical instruments supplier’s stock after buying an additional 535,958 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 2.24% of AngioDynamics worth $7,091,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ANGO. Quarry LP lifted its holdings in AngioDynamics by 75.1% in the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 2,594 shares during the last quarter. CWM LLC boosted its position in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after purchasing an additional 8,832 shares during the period. Mackenzie Financial Corp bought a new position in AngioDynamics during the 2nd quarter worth $80,000. Wealth Enhancement Advisory Services LLC acquired a new stake in AngioDynamics in the third quarter worth $86,000. Finally, AE Wealth Management LLC bought a new stake in AngioDynamics in the second quarter valued at $87,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Transactions at AngioDynamics

In other news, CEO James C. Clemmer acquired 20,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were bought at an average price of $6.03 per share, with a total value of $120,600.00. Following the acquisition, the chief executive officer now owns 681,582 shares of the company’s stock, valued at $4,109,939.46. This trade represents a 3.02 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have purchased 22,568 shares of company stock worth $135,847. Insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a report on Friday, October 4th. Canaccord Genuity Group cut their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th.

AngioDynamics Stock Performance

Shares of ANGO opened at $6.95 on Friday. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $8.25. The company has a market capitalization of $282.38 million, a PE ratio of -1.11 and a beta of 0.67. The company’s 50 day moving average price is $6.97 and its 200 day moving average price is $6.78.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm had revenue of $67.50 million for the quarter, compared to the consensus estimate of $67.93 million. During the same quarter in the prior year, the company posted ($0.12) earnings per share. The firm’s revenue was down 14.2% on a year-over-year basis. On average, equities analysts forecast that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.